Drugs / Ziltivekimab
Ziltivekimab
also known as
COR-001 · MEDI5117 · NN-6018 · WBP-216 · Ziltivekimab B · Ziltivekimab C · Ziltivekimab D
Monoclonal antibody targets IL6 via inhibition
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05721989 | Feb 2023 → Jan 2024 | — | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT05379829 | May 2022 → Jun 2024 | chronic kidney disease | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01559103 | May 2012 → Feb 2014 | rheumatoid arthritis | Novo Nordisk A/S | Terminated | No outcome recorded |
| Phase 1/21 trial · 1 met primary | ||||||
| Phase 1/2 | NCT02868229 | Sep 2016 → Dec 2018 | anemia | Novo Nordisk A/S | Completed | Met primary |
| Phase 22 trials · 2 met primary | ||||||
| Phase 2 | NCT04626505 | Oct 2020 → Aug 2021 | chronic kidney disease | Novo Nordisk A/S | Completed | Met primary |
| Phase 2 | NCT03926117 | Jun 2019 → Jun 2020 | chronic kidney disease | Novo Nordisk A/S | Completed | Met primary |
| Phase 35 trials | ||||||
| Phase 3 | NCT07276282 | Dec 2025 → Sep 2028 expected | acute myocardial infarction, coronary atherosclerosis | ECRI bv | Recruiting | No outcome recorded |
| Phase 3 | NCT07301034 | Dec 2025 → Nov 2028 expected | myocardial infarction | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 3 | NCT06118281 | Jun 2024 → Dec 2026 expected | acute myocardial infarction | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 3 | NCT06263244 | May 2024 → Jul 2026 overdue | atherosclerosis | Academic Medical Center - University of Amsterdam | Recruiting | No outcome recorded |
| Phase 3 | NCT05636176 | May 2023 → Jul 2027 expected | heart failure | Novo Nordisk A/S | Active not recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT03126318 Comparator | May 2017 → Mar 2019 | chronic kidney disease | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 3 | NCT06200207 Comparator | Apr 2024 → Oct 2026 expected | heart failure | Novo Nordisk A/S | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-07-31 | Novo Nordisk A/S | Results Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation novonordisk.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-07-31 | Novo Nordisk A/S | Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation novonordisk.com ↗ |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ziltivekimab | “A phase 1 trial of ziltivekimab, a fully human mAb against IL-6, was conducted in patients with moderate-to-severe nondialysis-dependent CKD” PMID 35373026 ↗ Dec 2020 |
| Known as | COR-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03126318 ↗ |
| Known as | MEDI5117 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01559103 ↗ |
| Known as | NN-6018 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297732 ↗ |
| Known as | WBP-216 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297732 ↗ |
| Known as | Ziltivekimab B | “Participants will receive a single subcutaneous (s.c.) injection of 15 milligram (mg) ziltivekimab B (15 milligrams per milliliter [mg/mL]) by single-use pre-filled manual...” NCT05721989 ↗ |
| Known as | Ziltivekimab C | “Participants will receive a single s.c. injection of 15 mg ziltivekimab C (30 mg/mL) by single-use pre-filled syringe assembled into a shield-activated pen-injector on Day 1.” NCT05721989 ↗ |
| Known as | Ziltivekimab D | “Participants will receive a single s.c. injection of 15 mg ziltivekimab D (15 mg/mL) by single-use pre-filled manual syringe on Day 1.” NCT05721989 ↗ |
| Action | Inhibit | “MEDI5117 (anti-IL-6)” NCT01559103 ↗ |
| Modality | Monoclonal antibody | “a fully human mAb against IL-6” PMID 35373026 ↗ Dec 2020 |
| Route | Intravenous | “Intravenous infusion administered over 60 minutes” NCT01559103 ↗ |
| Target | IL6 | “MEDI5117 (anti-IL-6)” NCT01559103 ↗ |